The Battle for Jet Lag Relief: A Controversial Decision
In a recent development, Vanda Pharmaceuticals has received a decision letter from the U.S. Food and Drug Administration (FDA) regarding their supplemental New Drug Application (sNDA) for HETLIOZ®, a potential treatment for jet lag disorder. The letter, however, brings a twist to the story.
While the FDA acknowledged the positive efficacy shown in Vanda's clinical trials, they concluded that the data fell short of providing substantial evidence for jet lag disorder treatment. The reason? The FDA believes that the controlled phase advance protocols used in the trials, which simulated bedtime shifts, were not analogous enough to real-world jet travel experiences. They argue that jet travel involves additional factors like reduced oxygen pressure, physical constraints, noise, and lighting changes, which were not accounted for in the trials.
But here's where it gets controversial...
Vanda respectfully disagrees with the FDA's interpretation. They emphasize that phase advance models are widely accepted in circadian rhythm research as valid and reliable methods to simulate the core circadian misalignment underlying eastward jet lag, which is the primary cause of jet lag symptoms. These models, according to Vanda, accurately reproduce the essential features of jet lag without the confounding variables of travel conditions, which are unrelated to the disorder itself.
Vanda's studies, including both simulated and actual transatlantic travel scenarios, demonstrate the meaningful benefits of tasimelteon (the active ingredient in HETLIOZ®) on sleep duration, latency to persistent sleep, and next-day alertness. Furthermore, tasimelteon has an established safety profile, with predominantly mild adverse events, and has been on the market for over 10 years for other approved indications.
And this is the part most people miss...
Vanda believes that their submitted dataset meets the statutory standard for substantial evidence of effectiveness on clinically relevant endpoints for jet lag disorder. They highlight a previous ruling by the D.C. Circuit in August 2025, which set aside the FDA's prior refusal to approve HETLIOZ® for jet lag disorder. The court described Vanda's evidence as "specific, reasoned, and rooted in evidence" and criticized the FDA's previous review as "cursory."
Following this ruling, Vanda and the FDA entered a collaborative framework agreement in October 2025, with the FDA committing to an expedited re-review of the sNDA by January 7, 2026, including consideration of narrowed, sleep-focused indications. Vanda appreciates the FDA's engagement but feels that the current decision does not fully reflect the collaborative spirit or address the court's concerns regarding meaningful engagement with the evidence.
So, what's next?
Vanda remains committed to working constructively with the FDA and exploring all appropriate avenues to gain approval for HETLIOZ® as a treatment for jet lag disorder. They aim to make this potential therapy available to travelers, addressing a significant unmet medical need. This ongoing dialogue between Vanda and the FDA highlights the complexities of drug approval processes and the importance of scientific evidence in healthcare decisions.
Thought-provoking questions:
- Do you think the FDA's decision is justified, or should they consider Vanda's arguments more closely?
- How important is it to simulate real-world travel conditions in clinical trials for jet lag disorder?
- Should the FDA prioritize collaborative efforts with pharmaceutical companies to ensure the best possible outcomes for patients?
